The hemp-derived cannabidiol (CBD) industry in the US gained a legendary new celebrity spokesperson this week.

PLUS Products (CSE:PLUS,OTCQX:PLPRF) announced on Tuesday (September 17) that it is teaming up with American singer-songwriter John Legend as a part of the nationwide launch for its first hemp-derived CBD product line.


The California-based cannabis and hemp edibles company said in a press release that Legend will be tasked with advocating for the new line on behalf of the firm.

“I have been a believer in the benefits of CBD for some time,” said Legend. The “Ordinary People” singer added that PLUS’ commitment to producing high-quality product was a selling point for the partnership.

Shares for PLUS rose on Tuesday, starting the trading day at C$4.88 and closing at C$5.25, a value increase of 7.6 percent. As of 3:10 p.m. EDT on Thursday (September 19), the company was at C$4.89.

“We established our reputation in edibles by offering customers a consistent and precisely-dosed gummy using high-quality extracts,” said company CEO Jake Heimark.

The executive added that the PLUS CBD lines will expand from the firm’s home state of California to “nearly all fifty states overnight.”

PLUS’ new edibles line includes CBD gummies in three different flavors, and tout benefits for physical balance, energy and aiding sleep, the last of which is also a part of another partnership for the launch.

PLUS’ national launch comes thanks to the farm bill that was passed in the US last year. The bill legalized hemp, which effectively opened the doors for the production and sale of hemp-derived CBD products.

Legend not the only partnership for new PLUS products

Global sleep company Casper will be introducing PLUS’ new CBD and melatonin-infused sleep gummies to consumers.

“We’re always exploring new ways to improve sleep across the entire sleep arc — from sunset to sunrise,” Neil Parikh, chief strategy officer at Casper, said in a statement.

The CBD company reported total revenues of US$3.6 million in its second quarter this year, a 125 percent increase from the US$1.6 million in revenues reported in the same quarter last year.

There was also in increase in operating costs during the most recent quarter for the company. Costs totaled US$5.3 million in Q2 2019, up from US$1.3 million in Q2 2018, due to the hiring of key personnel and consulting fees, according to the company.

Celebrities join the industry

Legend joins a string of celebrities who have recently bought into CBD in the US. In July, rapper Jay-Z joined privately owned cannabis company Caliva as chief brand strategist. Whoopi Goldberg has also expressed her interest in the drug and has since created the Whoopi & Maya brand of cannabis-derived epsom salts and menstrual relief rubs.

Earlier this year, Martha Stewart joined forces with Canopy Growth (NYSE:CGC,TSX:WEED) to develop CBD products for the US market, through a partnership with Sequential Brands Group (NASDAQ:SQBG).

Similarly, rapper Wiz Khalifa holds a partnership with Canadian producer The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF) by way of his firm Khalifa Kush Enterprises.

“Canada is a very important place to me… it’s the perfect start for the international expansion of Khalifa Kush,” Khalifa said in a statement.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

NYSE | TSX: ACB

Aurora Cannabis Inc. (“Aurora” or the “Company”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today has announced today that it has entered into an agreement with a syndicate of underwriters led by BMO Capital Markets and ATB Capital Markets, under which the underwriters have agreed to buy on bought deal basis 12,000,000 units of the Company (the “Units”), at a price of US$10.45 per Unit for gross proceeds of approximately US$125 million (the “Offering”). Each Unit will be comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant will be exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

Trading resumes in:

Company: Revive Therapeutics Ltd.

Keep reading... Show less

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES /

Revive Therapeutics Ltd. (” Revive ” or the ” Company “) (CSE:RVV) ( USA : RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into an amended agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (collectively, the ” Underwriters “), to increase the size of its previously announced offering of units (the ” Equity Units “) at a price of $0.50 per Equity Unit. Under the amended terms, the Underwriters have agreed to purchase, on a bought deal basis, 40,000,000 Equity Units for gross proceeds to the Company of $20,000,000 (the ” Offering “). The over-allotment option granted to the Underwriters will proportionately increase to 15% of the Offering.

Keep reading... Show less

The new dispensary brings expanded access for patients in the growing communities of Central Florida

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 77th nationwide. The new, 5,100 sq. ft. location marks the Company’s first in Summerfield expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”).

The Company announced today that its board of directors have approved a private placement of up to 15,000,000 units at a price of $.40 per unit for gross proceeds of up to $6,000,000. Each unit will consist of one common share of the Company and one share purchase warrant. Each share purchase warrant will be exercisable to purchase an additional common share at a fixed price of $.45 per share for a period of one year from closing.

Keep reading... Show less